Horizon Therapeutics plc
Refine by
Families
1 products found

Horizon Therapeutics plc products

Pipeline

Horizon - Diffuse Cutaneous Systemic Sclerosis

A molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). We are conducting a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in idiopathic pulmonary fibrosis.